Marie Zhu
Chief Technology Officer WuXi XDC
Seminars
Thursday 5th November 2026
Dual-payload ADC Innovation Using WuXi XDC Proprietary Technologies
11:30 am
- WuXiDARx conjugation technology enables sequential, precise dual-conjugation, allowing the generation of flexible dual-payload ADC formats (2+6, 4+4, and 2+4) via a two-step interchain cysteine conjugation strategy
- A 2+6 dp-ADC pairing WuXiMMAE with WuXiTecan-2 enhanced efficacy and expanded the therapeutic index by 15-fold, while a 4+4 dp-ADC combining WuXiTecan-2 with WuXiATRi exhibited potent synergy, doubling antitumor activity
- Our proprietary WuXiDARx conjugation technology, together with WuXi Payload- Linker, provides a versatile platform for dp-ADCs with superior efficacy and safety, offering the potential to overcome Enhertu resistance, Dxd resistance, MMAE resistance, and intratumor heterogeneity
